These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24978034)

  • 21. Is CTLA-4 a master switch for peripheral T cell tolerance?
    Bluestone JA
    J Immunol; 1997 Mar; 158(5):1989-93. PubMed ID: 9036940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential.
    van de Ven K; Borst J
    Immunotherapy; 2015; 7(6):655-67. PubMed ID: 26098609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune checkpoint blockade therapy: the 2014 Tang Prize in Biopharmaceutical Science.
    Chen YS; Shen CR
    Biomed J; 2015; 38(1):5-8. PubMed ID: 25673064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lysophosphatidic Acid Is an Inflammatory Lipid Exploited by Cancers for Immune Evasion
    Mathew D; Torres RM
    Front Immunol; 2020; 11():531910. PubMed ID: 33584637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune Checkpoints as Therapeutic Targets in Autoimmunity.
    Paluch C; Santos AM; Anzilotti C; Cornall RJ; Davis SJ
    Front Immunol; 2018; 9():2306. PubMed ID: 30349540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CTLA4 gene variants in autoimmunity and cancer: a comparative review.
    Ghaderi A
    Iran J Immunol; 2011 Sep; 8(3):127-49. PubMed ID: 21931200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation.
    Wing K; Yamaguchi T; Sakaguchi S
    Trends Immunol; 2011 Sep; 32(9):428-33. PubMed ID: 21723783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Critical co-stimulatory pathways in the stability of Foxp3+ Treg cell homeostasis in Type I diabetes.
    Kornete M; Piccirillo CA
    Autoimmun Rev; 2011 Dec; 11(2):104-11. PubMed ID: 21875694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Manipulation of costimulatory pathways in autoimmune disease].
    Kaneko H; Nakajima A; Azuma M
    Nihon Rinsho; 1997 Jun; 55(6):1531-6. PubMed ID: 9200944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B7 family checkpoint regulators in immune regulation and disease.
    Ceeraz S; Nowak EC; Noelle RJ
    Trends Immunol; 2013 Nov; 34(11):556-63. PubMed ID: 23954143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T-cell co-stimulatory blockade in transplantation: two steps forward one step back!
    Riella LV; Sayegh MH
    Expert Opin Biol Ther; 2013 Nov; 13(11):1557-68. PubMed ID: 24083381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent Advances in Costimulatory Blockade to Induce Immune Tolerance in Liver Transplantation.
    Ding M; He Y; Zhang S; Guo W
    Front Immunol; 2021; 12():537079. PubMed ID: 33732228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development.
    Ewing MM; Karper JC; Abdul S; de Jong RC; Peters HA; de Vries MR; Redeker A; Kuiper J; Toes RE; Arens R; Jukema JW; Quax PH
    Int J Cardiol; 2013 Oct; 168(3):1965-74. PubMed ID: 23351788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the treatment of metastatic melanoma: new immunomodulatory agents.
    Sznol M
    Semin Oncol; 2012 Apr; 39(2):192-203. PubMed ID: 22484191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint inhibition in lymphoid disease.
    Eyre TA; Collins GP
    Br J Haematol; 2015 Aug; 170(3):291-304. PubMed ID: 25824455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
    Hamid O; Carvajal RD
    Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T cell tolerance and autoimmunity.
    Abbas AK; Lohr J; Knoechel B; Nagabhushanam V
    Autoimmun Rev; 2004 Nov; 3(7-8):471-5. PubMed ID: 15546793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection.
    Suneetha PV; Pischke S; Schlaphoff V; Grabowski J; Fytili P; Gronert A; Bremer B; Markova A; Jaroszewicz J; Bara C; Manns MP; Cornberg M; Wedemeyer H
    Hepatology; 2012 Mar; 55(3):695-708. PubMed ID: 22006345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of peripheral T-cell deletion in transplantation tolerance.
    Wells AD; Li XC; Strom TB; Turka LA
    Philos Trans R Soc Lond B Biol Sci; 2001 May; 356(1409):617-23. PubMed ID: 11375065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.